PURPOSE OF REVIEW: Although a large number of novel broadly neutralizing antibodies has been recently described, the induction of such antibodies via vaccination has proven difficult. By contrast, nonneutralizing antibodies arise early during infection and have been repeatedly associated with both protection from infection and disease progression. RECENT FINDINGS: We are beginning to gain new insights into the broader landscape of antiviral mechanisms that nonneutralizing antibodies may harness to fight HIV, providing an unprecedented breadth of approaches by which HIV can be blocked and contained. SUMMARY: In this review, we summarize the characteristics of nonneutralizing antibodies, their role in HIV infection, and new paradigm-shifting functions that may be exploited by next-generation vaccine approaches aimed at blocking HIV infection.
PURPOSE OF REVIEW: Although a large number of novel broadly neutralizing antibodies has been recently described, the induction of such antibodies via vaccination has proven difficult. By contrast, nonneutralizing antibodies arise early during infection and have been repeatedly associated with both protection from infection and disease progression. RECENT FINDINGS: We are beginning to gain new insights into the broader landscape of antiviral mechanisms that nonneutralizing antibodies may harness to fight HIV, providing an unprecedented breadth of approaches by which HIV can be blocked and contained. SUMMARY: In this review, we summarize the characteristics of nonneutralizing antibodies, their role in HIV infection, and new paradigm-shifting functions that may be exploited by next-generation vaccine approaches aimed at blocking HIV infection.
Authors: Donald N Forthal; Gary Landucci; Kelly Stefano Cole; Marta Marthas; Juan C Becerra; Koen Van Rompay Journal: J Virol Date: 2006-09 Impact factor: 5.103
Authors: Debrah I Boeras; Peter T Hraber; Mackenzie Hurlston; Tammy Evans-Strickfaden; Tanmoy Bhattacharya; Elena E Giorgi; Joseph Mulenga; Etienne Karita; Bette T Korber; Susan Allen; Clyde E Hart; Cynthia A Derdeyn; Eric Hunter Journal: Proc Natl Acad Sci U S A Date: 2011-11-07 Impact factor: 11.205
Authors: Teemu T Junttila; Kathryn Parsons; Christine Olsson; Yanmei Lu; Yan Xin; Julie Theriault; Lisa Crocker; Oliver Pabonan; Tomasz Baginski; Gloria Meng; Klara Totpal; Robert F Kelley; Mark X Sliwkowski Journal: Cancer Res Date: 2010-05-18 Impact factor: 12.701
Authors: Kaustuv Banerjee; P J Klasse; Rogier W Sanders; Florencia Pereyra; Elizabeth Michael; Min Lu; Bruce D Walker; John P Moore Journal: AIDS Res Hum Retroviruses Date: 2010-04 Impact factor: 2.205
Authors: Amy W Chung; Jenniffer M Mabuka; Bongiwe Ndlovu; Anna Licht; Hannah Robinson; Yathisha Ramlakhan; Musie Ghebremichael; Tarylee Reddy; Philip J R Goulder; Bruce D Walker; Thumbi Ndung'u; Galit Alter Journal: AIDS Date: 2018-06-19 Impact factor: 4.177
Authors: Kara Jensen; Myra Grace Dela Pena; Robert L Wilson; Uma Devi K Ranganathan; William R Jacobs; Glenn Fennelly; Michelle Larsen; Koen K A Van Rompay; Pamela A Kozlowski; Kristina Abel Journal: Trials Vaccinol Date: 2013-11-01
Authors: Amber Dunkel; Shixue Shen; Celia C LaBranche; David Montefiori; James P McGettigan Journal: AIDS Res Hum Retroviruses Date: 2015-05-05 Impact factor: 2.205
Authors: Jeffrey R Schneider; Xiaoying Shen; Chiara Orlandi; Tinashe Nyanhete; Sheetal Sawant; Ann M Carias; Archer D Smith; Neil L Kelleher; Ronald S Veazey; George K Lewis; Georgia D Tomaras; Thomas J Hope Journal: J Virol Date: 2020-02-14 Impact factor: 5.103
Authors: Philipp Kolb; Steven Sijmons; Matthew R McArdle; Husam Taher; Jennie Womack; Colette Hughes; Abigail Ventura; Michael A Jarvis; Christiane Stahl-Hennig; Scott Hansen; Louis J Picker; Daniel Malouli; Hartmut Hengel; Klaus Früh Journal: J Virol Date: 2019-02-05 Impact factor: 5.103